As blockbuster drugs approach patent expiration, life sciences companies face significant revenue risk. Strategic patent portfolio management, validity analysis, and innovation planning can help organizations protect value and maintain competitive advantage beyond loss of exclusivity.

As billions in drug patents expire, the pharmaceutical industry faces a looming patent cliff. Biotech innovators must rethink IP protection to safeguard revenue and innovation. This article explores trade secrets, continuous filings, data ownership, and regulatory exclusivity, strategies that help companies adapt and thrive beyond patent loss.